Publication
Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (8)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 8
- cancerMalignant Breast Neoplasmcivic_curation1.00
- drugMTOR Kinase Inhibitor AZD8055civic_curation1.00
- drugRapaLink-1civic_curation1.00
- drugSirolimuscivic_curation1.00
- geneMTORcivic_curation1.00
- variantMTOR A2034Vcivic_curation1.00
- variantMTOR F2108Lcivic_curation1.00
- variantMTOR M2327Icivic_curation1.00
Curated evidence
Evidence citing this paper (7)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 27279227
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| MTOR A2034V2 | ||||||||
| MTOR Kinase Inhibitor AZD8055 + RapaLink-1Substitutes | Malignant Breast Neoplasm | Predictive | D | Does Not Support Resistance | 4 | accepted | EID1548MCF-7 breast cancer cell line was exposed to mTOR inhibitor rapamycin until resistance developed. Deep sequencing revealed an MTOR A2034V mutation in the resistant clone (RR1). Downstream signalling w… (full text at CIViC) PMID 27279227 · Rodrik-Outmezguine et al., 2016 · Open in CIViC | civic |
| Sirolimus | Malignant Breast Neoplasm | Predictive | D | Supports Resistance | 4 | accepted | EID1547MCF-7 breast cancer cell line was exposed to mTOR inhibitor rapamycin until resistance developed. Deep sequencing revealed an MTOR A2034V mutation in the resistant clone. Downstream signalling was ind… (full text at CIViC) PMID 27279227 · Rodrik-Outmezguine et al., 2016 · Open in CIViC | civic |
| MTOR F2108L1 | ||||||||
| Sirolimus | Malignant Breast Neoplasm | Predictive | D | Supports Resistance | 4 | accepted | EID1543MCF-7 breast cancer cell line was exposed to mTOR inhibitors AZD8055 or rapamycin until resistance developed. Deep sequencing revealed an MTOR F2108L mutation in rapamycin-resistant clones (RR2 cells)… (full text at CIViC) PMID 27279227 · Rodrik-Outmezguine et al., 2016 · Open in CIViC | civic |
| MTOR M2327I4 | ||||||||
| MTOR Kinase Inhibitor AZD8055 | Malignant Breast Neoplasm | Predictive | D | Supports Resistance | 4 | accepted | EID1544MCF-7 breast cancer cell line was exposed to mTOR inhibitor AZD8055 until resistance developed. Deep sequencing revealed an MTOR M2327I mutation in the AZD8055-resistant clone. Downstream signalling w… (full text at CIViC) PMID 27279227 · Rodrik-Outmezguine et al., 2016 · Open in CIViC | civic |
| RapaLink-1 + SirolimusSubstitutes | Malignant Breast Neoplasm | Predictive | D | Does Not Support Resistance | 3 | accepted | EID1545MCF-7 breast cancer cell line was exposed to mTOR inhibitor AZD8055 until resistance developed. Deep sequencing revealed an MTOR M2327I mutation in the AZD8055-resistant clone. These cells remained se… (full text at CIViC) PMID 27279227 · Rodrik-Outmezguine et al., 2016 · Open in CIViC | civic |
| Sirolimus | Malignant Breast Neoplasm | Predictive | D | Supports Resistance | 4 | rejected | EID1546MCF-7 breast cancer cell line was exposed to mTOR inhibitor rapamycin until resistance developed. Deep sequencing revealed an MTOR A2034V mutation in the resistant clone. Downstream signalling was ind… (full text at CIViC) PMID 27279227 · Rodrik-Outmezguine et al., 2016 · Open in CIViC | civic |
| RapaLink-1 + SirolimusSubstitutes | Malignant Breast Neoplasm | Predictive | D | Supports Sensitivity Response | 4 | rejected | EID10082MCF-7 breast cancer cell line was exposed to mTOR inhibitor AZD8055 until resistance developed. Deep sequencing revealed an MTOR M2327I mutation in the resistant clone (TKi-R). A novel mTOR inhibitor … (full text at CIViC) PMID 27279227 · Rodrik-Outmezguine et al., 2016 · Open in CIViC | civic |